QUALITY OF LIFE UNIT
Universal Haptic Drive A low cost clinical device for comprehensive rehabilitation of the upper arm and wrist Universal Haptic Drive Motivation The aim of robotically assisted rehabilitation (RAR) is to increase the efficiency in the delivery of rehabilitation care for stroke patients while simultaneously improving the quality of that care. The immediate and growing population of persons with upper limb impairments, particularly from incidents of stroke, is well known as a combined result of increasing life expectancies, increasing population of elderly, and the increased prevalence of stroke with age. Currently worldwide, 15 million persons suffer a stroke each year and 5 million persons are left with permanent disability. Studies have shown that early rehabilitation after the onset of stroke, which is generally organized by clinician in the hospital or rehabilitation center, is critical for optimal stroke recovery.
The Universal Haptic Drive (UHD) project aims at developing a low-cost technology for rehabilitation of neuromuscular impairment in the upper extremities. The patented UHD system is composed of: (1) a pantograph mechanism with three lockable joints allowing eight operational training modes that train various forms of arm reach and wrist orientation; (2) an integrated spring suspension system that allows the amount of limb weight supported by the user to be measured and adjusted; and (3) two low-cost actuators that provide power to the system in each of the 8 training modes through an inherently safe and compliant series elastic actuation system.
Therefore, successful delivery of early therapy can maximize chances of recovery as well as reduce further cost of the rehabilitation program after discharge from the hospital.
Universal Haptic Drive Market The principle market for the Universal Haptic Drive is in training patients in the clinical environment for early training. The technology can be extended to a variety of impairments stemming from orthopedic injury, surgery, or neuromuscular disorders. The initial point of market introduction is through clinical treatment of acute- and sub-acute stroke, where general acceptance of the technology by patients, physicians, and clinicians will lead to further technology endorsement, prescription, and reimbursement.